Moreover, the ability of SGLT2 inhibitors to control arrhythmias is linked to several cardiovascular benefits, including reduced atrial remodeling (due to lower blood pressure and LV mass), anti-inflammatory and anti-fibrotic effects, and improved mitochondrial function and energy metabolism in the heart [34]. The gene discussed is SLC5A2; the disease is Arrhythmia.